T1	Participants 432 501	Eighty-eight chemotherapy-na√Øve metastatic pancreatic cancer patients
T2	Participants 1178 1243	patients with EGFR mutations than in those without EGFR mutations
T3	Participants 1408 1483	metastatic pancreatic cancer patients, especially those with EGFR mutations
T4	Participants 26 91	pancreatic cancer with epidermal growth factor receptor mutations
